Shilpa Medicare receives US approval for Varenicline Tablets, 0.5 mg and 1 mg
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Mantri will replace V. S. Mani, Executive Director & Global Chief Financial Officer of the company as he has conveyed his decision to opt for early retirement
NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court
Introduces revolutionary approach to workflow management to enhance operational efficiency and optimize process efficiency
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Findings likely to generate hypotheses about potential new uses of drugs
The portfolio includes branded injectable cephalosporines for infectious diseases
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Subscribe To Our Newsletter & Stay Updated